Affordable Access

deepdyve-link
Publisher Website

Diverse mechanisms of autophagy dysregulation and their therapeutic implications: does the shoe fit?

Authors
  • Sathiyaseelan, Paalini1, 2
  • Rothe, Katharina3, 4
  • Yang, Kevin C1, 2
  • Xu, Jing1, 2
  • Chow, Norman S1
  • Bortnik, Svetlana1
  • Choutka, Courtney1
  • Ho, Cally1, 2
  • Jiang, Xiaoyan3, 4
  • Gorski, Sharon M1, 2
  • 1 a Canada's Michael Smith Genome Sciences Centre , British Columbia Cancer Agency , Vancouver , BC , Canada. , (Canada)
  • 2 b Department of Molecular Biology and Biochemistry , Simon Fraser University , Burnaby , BC , Canada. , (Canada)
  • 3 c Terry Fox Laboratory , British Columbia Cancer Agency , Vancouver , BC , Canada. , (Canada)
  • 4 d Department of Medical Genetics , University of British Columbia , Vancouver , BC , Canada. , (Canada)
Type
Published Article
Journal
Autophagy
Publisher
Landes Bioscience
Publication Date
Feb 01, 2019
Volume
15
Issue
2
Pages
368–371
Identifiers
DOI: 10.1080/15548627.2018.1509609
PMID: 30153072
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

In its third edition, the Vancouver Autophagy Symposium presented a platform for vibrant discussion on the differential roles of macroautophagy/autophagy in disease. This one-day symposium was held at the BC Cancer Research Centre in Vancouver, BC, bringing together experts in cell biology, protein biochemistry and medicinal chemistry across several different disease models and model organisms. The Vancouver Autophagy Symposium featured 2 keynote speakers that are well known for their seminal contributions to autophagy research, Dr. David Rubinsztein (Cambridge Institute for Medical Research) and Dr. Kay F. Macleod (University of Chicago). Key discussions included the context-dependent roles and mechanisms of dysregulation of autophagy in diseases and the corresponding need to consider context-dependent autophagy modulation strategies. Additional highlights included the differential roles of bulk autophagy versus selective autophagy, novel autophagy regulators, and emerging chemical tools to study autophagy inhibition. Interdisciplinary discussions focused on addressing questions such as which stage of disease to target, which type of autophagy to target and which component to target for autophagy modulation. Abbreviations: AD: Alzheimer disease; AMFR/Gp78: autocrine motility factor receptor; CCCP: carbonyl cyanide m-chlorophenylhydrazone; CML: chronic myeloid leukemia; CVB3: coxsackievirus B3; DRPLA: dentatorubral-pallidoluysian atrophy; ER: endoplasmic reticulum; ERAD: ER-associated degradation; FA: focal adhesion; HCQ: hydroxychloroquine; HD: Huntingtin disease; HIF1A/Hif1α: hypoxia inducible factor 1 subunit alpha; HTT: huntingtin; IM: imatinib mesylate; MAP1LC3B: microtubule associated protein 1 light chain 3 beta; NBR1: neighbour of BRCA1; OGA: O-GlcNAcase; PDAC: pancreatic ductal adenocarcinoma; PLEKHM1: pleckstrin homology and RUN domain containing M1; polyQ: poly-glutamine; ROS: reactive oxygen species; RP: retinitis pigmentosa; SNAP29: synaptosome associated protein 29; SPCA3: spinocerebellar ataxia type 3; TNBC: triple-negative breast cancer.

Report this publication

Statistics

Seen <100 times